SB-431542

SB-431542
Identifiers
ChEBI CHEBI:91108 YesY
ChEMBL ChEMBL440084
ChemSpider 3716512
8216
Jmol interactive 3D Image
PubChem 4521392
Properties
C22H16N4O3
Molar mass 384.4
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7.[1] (It is NOT an ALK inhibitor).

In-vitro studies

It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans.[1]

As of January 2016 There are no clinical trials registered for SB-431542 for cancer or any other indication.[2]

In vitro use

The treatment with SB431542 is a robust, clinically applicable, and efficient system for generating mesenchymal stem/stromal cells (MSCs) from human iPSCs.[3]

References

  1. 1 2 Laping, NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA (2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology 62 (1): 58–64. doi:10.1124/mol.62.1.58. PMID 12065755.
  2. Search results for SB-431542
  3. Chen Y S, Pelekanos R A., Ellis R L., et al and Nicholas M. Fisk (2012). Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells Stem Cells Trans Med., 1(2), 83-95 doi:10.5966/sctm.2011-0022

References

    This article is issued from Wikipedia - version of the Friday, February 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.